Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Get Help Today

Looking for help or additional information? Contact us today.
First Name:
Last Name:
Email:
Phone:
Zip Code:
Comments:
Please enter the number below:
5753
Conditions: Cancer
Start Date: November 1, 2005
Phase: Phase II
Status: Completed
NCT ID: NCT00222729
Study Type: Interventional
Intervention: Drug: Pemetrexed|Drug: Bevacizumab
Study Design: Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Results: No Results Available
Sponsors: University of Pittsburgh|Eli Lilly and Company|Genentech
Ages: Adult|Senior
Enrollment: 20
Funded By: Other|Industry
First Received: September 16, 2005
End Date: September 1, 2009
Last Updated: April 30, 2010
Last Verified: April 1, 2010